Re-Admission/Hospitalization Form (ADM)

Web Version: 1.0; 4.07; 10-16-15

Segment (PROTSEG): Date of Admission (ADMITDT):	
1. Date of discharge:(<i>DISCHDT</i>)	(mm/dd/yyyy)
2. Patient discharge status: (DISCPTST)	1 - Alive 2 - Dead If Dead, a Death Form must be submitted.
3. Record PRIMARY discharge diagnosis:(PHSPREAS)	O1 - GVHD O2 - Relapse/Progression O3 - Graft Failure O4 - Infection O5 - Fungal Infection *Additional O ptions Listed Below
*Specify organ: (ADM4SPEC)	
**Specify other:(ADM1SPEC)	
4. Record secondary discharge diagnoses:	
a. GVHD:(<i>REASGVHD</i>)	1 - Contributory 2 - Noncontributory ?
b. Relapse/progression: (REASRLPS)	1 - Contributory 2 - Noncontributory
c. Graft failure:(REASGF)	1 - Contributory 2 - Noncontributory
d. Infection: (REASINF)	1 - Contributory 2 - Noncontributory
e. Fever: (REASFVR)	1 - Contributory 2 - Noncontributory
f. Se izure: (REAS SZR)	1 - Contributory 2 - Noncontributory
g. Bleeding/hemorrhage: (REAS GIBL)	1 - Contributory 2 - Noncontributory
h. Diarrhea: (REASDRH)	1 - Contributory 2 - Noncontributory
i. Nausea/vomiting:(REASNV)	1 - Contributory 2 - Noncontributory
j. Organ failure: <i>(REAS ORGF)</i> Specify organ: <i>(ADM 3SPEC)</i>	1 - Contributory 2 - Noncontributory
k. Trauma:(REASTRAM)	1 - Contributory 2 - Noncontributory
I. Psychiatric:(REASPSYC)	1 - Contributory 2 - Noncontributory
m. Se ∞ ndary malignancy:(REA SMALG)	1 - Contributory 2 - Noncontributory
n. Sche duled procedure/treatment: (REASPROC)	1 - Contributory 2 - Noncontributory
o. Th romb osis/th rombus/emb olism: (REASTRMB)	1 - Contributory 2 - Noncontributory
p. Other:(REASOTHR)	1 - Contributory 2 - Noncontributory
Specify other:(ADM2SPEC)	
5. Record re-admission institution:(ADM CENTR)	1 - O riginal Transplant Center 2 - O ther Transplant Center 3 - O ther Hospital
Comments:(ADM COMM1)	

Additional Selection Options for ADM

Record PRIMARY discharge diagnosis:

- 06 Non-Fungal Infection 07 - Fever 08 - Seizure
- 09 Bleeding/Hemorrhage
- 10 Diarrhea
- 11 Nausea/Vomiting12 Organ Failure (specify organ)*
- 13 Trauma 14 Psychiatric

- 15 Secondary Malignancy
 16 Transplant
 17 Scheduled Procedure/Treatment
- 18 Thrombosis/Thrombus/Embolism
- 99 Other (specify)**

Adverse Event Form (AE1)

Web Version: 1.0; 4.00; 10-16-15

Segment (PROTSEG):
Date of Onset (ADVDATE):
Event description (ADVENT):

1. Report activation status:(A VSTATUS) 1 - Keep report active 2 - Deactivate - Report filed in error 3 - Deactivate - Key field error 9 - Deactivate - Other reason If Other, specify reason for deactivation:(AESPEC1) 2. Record date transplant center became aware of the event: (AVA WA RDT) (mm/dd/yyyy) 3. Indicate weight at time of the event: (AVWGHTKG) (xxx.x) kg 4. Was this event expected or anticipated? (A VEXPECT) ☐ 2 - No ☐ 1 - Yes 5. Record the severity of event: (AVEVENT) 1 - Mild 2 - Moderate 3 - Severe 4 - Life Threatening 5 - Fatal 6. What is the relationship to study therapy/intervention: (AVRELAT) 1 - Unrelated 2 - Unlikely 3 - Possible 4 - Probable 5 - Definite 7. Is there an alternative etiology: (AVETIOL) O - None Apparent 1 - Study Disease 2 - Other Pre-Existing Disease or Condition 3 - Accident, Trauma, or External Factors 4 - Concurrent Illness/Condition (Not Pre-Existing) 8. What is the effect on study the rapy/intervention schedule: (AVEFFECT) 1 - No Change - Completed 2 - No Change - Ongoing 3 - Dose Modified 4 - Temporarily S topped 5 - Permanently Stopped 9. Record the most severe outcome of the event: (AVOUTCOM) 1 - Resolved, No Residual Effects 2 - Resolved with Seguelae 3 - Persistent Conditon 4 - Resolved by Death 10. Record the date of resolution: (AVRESDT) (mm/dd/yyyy) ? 11. Was this event associated with:(A VASS OCI) O - None of the Following 1 - Death 2 - Life-Threatening Event 3 - Disability 4 - Congenital Anomaly *Additional Options Listed Below

Comments:(AE1COMM)	

Additional Selection Options for AE1

- Was this event associated with:
 5 Required Intervention to Prevent Permanent Impairment or Damage
 6 Hospitalization (Initial or Prolonged)
 9 Other SAE

AE Sumi	mary Form (AE2)		
Segment (PROTSEG): Date of Onset (ADVDATE): Event description (ADVENT):		Web Version: 1.	0; 3.12; 10-16-15
1. Report activation status: (AVSTAT_A)	1 - Keep reportactive 2 - Deactivate - Report filed in error 3 - Deactivate - Key field error 9 - Deactivate - Other reason		
Relevant Past Medical History 2. Does the patient have any relevant history, including pre-existing medical conditions?(SEMEDHXS) If Yes, include any relevant history, including preexisting medical conditions be	☐ 1 - Yes ☐ 2 - No		
3. Event Summary Include clinical history of event, associated signs and symptoms, alternative etiol (SESUMM)	logies being considered and medical management b	elo w.	
4. Initial submitter: (SEISUBBY)	Name: Da	ate:(SE/SUBDT)	(mm/dd
5. Authorized submitter:(SEAS UBBY)		ate:(SEASUBDT)	(mm/dd

AE Therapy Form (AE3)

Web Version: 1.0; 4.05; 10-16-15

Segment (PROTSEG): Date of Onset (ADVDATE): Event description (ADVENT):

1. Report activation status: (AVSTAT_B)

- 1 Keep reportactive
- 2 Deactivate Report filed in error
- 3 Deactivate K ey field error 9 Deactivate O therreason

Study Product/Suspect Medication Data

If Yes, list the study product/suspect medications the subject was taking in the grid below.

Study Product Name (Note: If blinded, indicate as such)	Dose of Study Product(s) at SAE Onset	Route of Study Product(s) at SAE Onset	Schedule of Study Product(s) at SAE Onset	Date Study Product First Started (mm/dd/yyyy)	Date Study Product Last Taken (mm/dd/yyyy)	Reason for Use
(SPNAME1)	(SP1 DO SE)	(SP1ROUTE)	(SP1SCHED)	(SP1STDT)	(SP1SPDT)	(SP1REASO)
(SPNAME2)	(SP2 DO SE)	(SP2ROUTE)	(SP2 SCHED)	(SP2STDT)	(SP2SPDT)	(SP2REASO)
(SPNAME3)	(SP3DOSE)	(SP3ROUTE)	(SP3SCHED)	(SP3STDT)	(SP3SPDT)	(SP3REASO)
(SPNAME4)	(SP4DOSE)	(SP4ROUTE)	(SP4SCHED)	(SP4STDT)	(SP4SPDT)	(SP4REASO)
(SPNAME5)	(SP5DOSE)	(SP5ROUTE)	(SP5SCHED)	(SP5STDT)	(SP5SPDT)	(SP5REASO)

Concomitant Medications

3. Was the patient taking any	con comitant medications? (RCVCONMD)
-------------------------------	--------------------------------------

☐ 1 - Yes ☐ 2 - No

If Yes, list the concomitant medications the patient was taking up to 1 month prior to SAE onset in the grid below.

Me dication	Start Date (mm/dd/yyyy)	Stop Date (mm/dd/yyyy)	Dose, Route, Schedule	Indication
(CONMED1)	(CM1STDT)	(CM1SPDT)	(CM1DOSE)	(CM1INDIC) 1 - Treatment of adverse event 9 - Other
(CONMED2)	(CM2STDT)	(CM2SPDT)	(CM2DOSE)	(CM2 INDIC) 1 - Treatment of adverse event 9 - Other
(CONMED3)	(CM3STDT)	(CM3SPDT)	(CM3DOSE)	(CM3INDIC) 1 - Treatment of adverse event 9 - Other
(CONMED4)	(CM4STDT)	(CM4SPDT)	(CM4DOSE)	(CM4INDIC) 1 - Treatment of adverse event 9 - Other
(CONMED5)	(CM5STDT)	(CM5SPDT)	(CM5DOSE)	(CM5INDIC)

				1 - Treatment of adverse event
				9 - Other
(CONMED6)	(CM6STDT)	(CM6SPDT)	(CM6DOSE)	(CM6INDIC)
				1 - Treatment of adverse event 9 - Other
(CONMED7)	(CM7STDT)	(CM7SPDT)	(CM7DOSE)	(CM7INDIC)
				1 - Treatment of adverse event 9 - Other
(CONMED8)	(CM8STDT)	(CM8SPDT)	(CM8DOSE)	(CM8INDIC)
				1 - Trea tment of adverse event 9 - Other
(CONMED9)	(CM9STDT)	(CM9SPDT)	(CM9DOSE)	(CM9INDIC)
				1 - Trea tment of adverse event 9 - Other
(CONMED10)	(CM10STDT)	(CM10SPDT)	(CM 10DOSE)	(CM10INDI)
				1 - Treatment of adverse event 9 - Other
(CONMED11)	(CM11STDT)	(CM11SPDT)	(CM11DOSE)	(CM1 1INDI)
				1 - Treatment of adverse event 9 - Other
(CONMED12)	(CM12STDT)	(CM12 SPDT)	(CM 12DOSE)	(CM12INDI)
				1 - Treatment of adverse event 9 - Other
(CONMED13)	(CM13STDT)	(CM13SPDT)	(CM 13DOSE)	(CM13INDI)
				1 - Treatment of adverse event 9 - Other
(CONMED14)	(CM14STDT)	(CM14SPDT)	(CM 14DOSE)	(CM14INDI)
				1 - Trea tment of adverse event 9 - Other
(CONMED15)	(CM15STDT)	(CM15SPDT)	(CM 15DOSE)	(CM15INDI)
				1 - Trea tment of adverse event 9 - Other
(CONMED16)	(CM16STDT)	(CM16SPDT)	(CM16DOSE)	(CM16INDI)
				1 - Treatment of adverse event 9 - Other
(CONMED17)	(CM17STDT)	(CM17SPDT)	(CM 17DOSE)	(CM17INDI)
				1 - Trea tment of adverse event 9 - Other
(CONMED18)	(CM18STDT)	(CM18SPDT)	(CM 18DOSE)	(CM18INDI)
				1 - Trea tment of adverse event 9 - O ther
(CONMED19)	(CM19STDT)	(CM19SPDT)	(CM 19DOSE)	(CM19INDI)
				1 - Trea tment of adverse event 9 - O ther
(CONMED20)	(CM20STDT)	(CM20SPDT)	(CM20DOSE)	(CM20INDI)
				1 - Treatment of adverse event 9 - Other

(CONMED2 1)	(CM21STDT)	(CM21 SPDT)	(CM21DOSE)	(CM2 1INDI) 1 - Treatment of adverse event 9 - Other
(CONMED22)	(CM22STDT)	(CM22 SPDT)	(CM22DOSE)	(CM22INDI) 1 - Treatment of adverse event 9 - Other
(CONMED23)	(CM23STDT)	(CM23SPDT)	(CM23DOSE)	(CM23INDI) 1 - Treatment of adverse event 9 - Other
(CONMED24)	(CM24STDT)	(CM24SPDT)	(CM24DOSE)	(CM2 4INDI) 1 - Treatment of adverse event 9 - Other
(CONMED25)	(CM25STDT)	(CM25SPDT)	(CM25DOSE)	(CM25INDI) 1 - Treatment of adverse event 9 - Other
Comments:(AE3COMM)				

AE Laboratory/Diagnostics Form (AE4)

	la h	V = ==: =		. 2 4	4.4	0.46	4 6
v	veb	Versio	n: 1.u	J: 3.1	11: 1	()-1b-	1:

Segment (PROTSEG):
Date of Onset (ADVDATE):
Event description (ADVENT):

1. Report activation status: (AVSTAT_C)

- 1 Keep report active
- 2 Deactivate Report filed in error
- 3 Deactivate Key field error 9 Deactivate Otherreason

Laboratory Test Results

2. Were relevant laboratory tests performed?(LABTSTPF)

☐ 1 - Yes ☐ 2 - No

If Yes, record the relevant laboratory test results in the gird below.

Test	Collection Date (mm/dd/yyyy)	Result (Include units)	Site Normal Range (Include units)	Lab Value Previous to this SAE (Include units)	Collection Date for Previous Lab (mm/dd/yyyy)
(ADLTST1)	(ADL1CD)	(ADL1RES)	(ADL 1NORG)	(ADL1PRVL)	(ADL1PCD)
(ADLTST2)	(ADL2CD)	(ADL2 RES)	(ADL2NORG)	(ADL2PRVL)	(ADL2PCD)
(ADLTST3)	(ADL3CD)	(ADL3RES)	(ADL3NORG)	(ADL3PRVL)	(ADL3PCD)
(ADLTST4)	(ADL4CD)	(ADL4RES)	(ADL4NORG)	(ADL4PRVL)	(ADL4PCD)
(ADLTST5)	(ADL5CD)	(ADL5RES)	(ADL5NORG)	(ADL5PRVL)	(ADL5PCD)
(ADLTST6)	(ADL6CD)	(ADL6RES)	(ADL6NORG)	(ADL6PRVL)	(ADL6PCD)
(ADLTST7)	(ADL7CD)	(ADL7RES)	(ADL7NORG)	(ADL7PRVL)	(ADL7PCD)
(ADLTST8)	(ADL8CD)	(ADL8RES)	(ADL8NORG)	(ADL8PRVL)	(ADL8PCD)
(ADLTST9)	(ADL9CD)	(ADL9RES)	(ADL9NORG)	(ADL9PRVL)	(ADL9PCD)
(ADLTST10)	(ADL10CD)	(ADL10RES)	(ADL 10NRG)	(ADL10PVL)	(ADL10PCD)

Diagnostic Tests (EX: MR, CT Scan, Ultrasound)

Were relevant diagnostic tests	performed?(DXSTPF)
--	--------------------

☐ 1 - Yes ☐ 2 - No

 ${\it If Yes, record the relevant diagnostic test results in the grid below. Submit copies of the diagnostic test if available.}$

Test Date Performed (mm/dd/yyyy)	Results/Comments
----------------------------------	------------------

(ADDTS1)	(AD1DTDAT)	
		(AD1DTRES)
(ADDTS2)	(AD2DTDAT)	
		(AD2DTRES)
(ADDTS3)	(AD3DTDAT)	
		(AD3DTRES)
(ADDTS4)	(AD4DTDAT)	
		(40.40.70.50)
(ADDTSS)	(40507047)	(AD4DTRES)
(ADDTS5)	(AD5DTDAT)	
		(AD5DTRES)
	l .	(ADOD TALO)

(40,0,700)	(40007047)	
(ADDTS6)	(AD6DTDAT)	
		(40.00 TD TO)
		(AD6DTRES)
(ADDTS7)	(AD7DTDAT)	
(ADD 101)	(ADIDIDAT)	
		(AD7DTRES)
		(NETETALE)
(ADDTS8)	(AD8DTDAT)	
		(AD8DTRES)
(45,5700)	(45057547)	
(ADDTS9)	(AD9DTDAT)	
		(AD9DTRES)
(ADDTS10)	(AD10DTDT)	
, , ,	, , ,	
		(AD10DTRS)
	l .	1 · · · · · · · · · · · · · · · · · · ·

Comments:(AE4COMM)	

AE Review Form (AE5)

Veb Version: 1.0; 3.12; 10-16-15

7.2.1.0	(
Segment (PROTSEG): Date of Onset (ADVDATE): Event description (ADVENT):	Web Version
1. Report activation status: (AVSTAT_D)	1 - Keep reportactive 2 - Deac fivate - Report filed in error 3 - Deac fivate - K ey field error 9 - Deac fivate - O ther reason
2. Reviewed:(AEREVIEW)	1 - Yes 2 - No
3. Reviewed by: (ARFREVBY)	1.100 = 2.110
4. Review date: (ARFREVDT)	(mm/dd/yyyy)
5. Comment 1 - For Distribution:(ARCM1DIS)	
6. Comment 2 - All Other Reviewers/Data Coordinating Center(ARCM2ALL)	

1.0; 7.00; 10-16-15

AE Medical Moni	tor Reviewer Form (AE6)
Segment (PROTSEG): Date of Onset (ADVDATE): Event description (ADVENT):	Web Version: 1
1. Adverse event status: (AVSTAT_E)	1 - Keep reportactive 2 - Deactiva te - Report filed in error 3 - Deactiva te - K ey field error 9 - Deactiva te - O fier reason
2. Has this event been determined to be an unexpected, grade 3-5 adverse event? (AMDETER)	☐ 1 - Yes ☐ 2 - No
3. Does this require expedited reporting to the DSMB?(AMEXPDSM)	☐ 1 - Yes ☐ 2 - No
4. Do you recommend the patient be withdrawn from further protocol therapy? (AMWITHDR)	1 - Yes 2 - No
5. Is the review complete?(AMREVDNE)	1 - Yes 2 - No
7. Medical Monitor event description: (AMMMEVDS)	
8. Medical Monitor CTCAE grade of event: (CTCAEGRD)	1 - Grade 1 2 - Grade 2 3 - Grade 3 4 - Grade 4 5 - Grade 5
Comments:(AE6COMM)	

Baseline Form - 0902 (BL6)

Web Version: 1.0; 3.04; 10-16-15

Segment (PROTSEG): Visit Number (VISNO):

Pre-transplant Status

Pre-transplant Status	
Patient's primary diagnosis pre-transplant: (BLPRM DG)	O1 - A cute Myelogenous Leukemia (AML or ANLL) O2 - A cute Lymphoblastic Leukemia (ALL) O3 - O ther Acute Leukemia O4 - C hronic Myelogenous Leukemia (CML) O5 - O ther Leukemia *A dditional Options Listed Below
2. If Acute Leukemia, record the disease status pre-transplant: (BLACL)	1 - Primary Induction Failure 2 - First Complete Remission 3 - First Relapse 4 - Second Complete Remission 5 - Second Relapse *A dditional Options Listed Below
3. If CML, record the disease status pre-transplant:(BLCML)	O1 - First Chronic Phase O2 - Hema tologic Complete Remission O3 - A ccelerated Phase O4 - Blast Crisis O5 - S econd or Greater Chronic Phase
4. If Other Leukemia, specify primary diagnosis pre-transplant: (BLOTHLEU)	
5. If Other Leukemia, record the disease status pre-transplant: (BLOTLEUS)	
6. If MDS/MPS, record the disease status pre-transplant:(BLMDS)	Refractory Anemia Refractory Anemia with Ringed S ideroblasts Refractory Cytopenia with Multilineage Dysplasia Refractory Cytopenia with Multilineage Dysplasia and Ringed S ideroblasts Refractory Anemia with Excess Blasts - 1 (5-10% blasts) Additional Options Listed Below
7. If Multiple Myeloma/PCD, record the disease status pre-transplant: (BLMYELOM)	O1 - S tringent Complete Response (sCR) O2 - Complete Response (CR) O3 - Near Complete Response (nCR) O4 - Very Good Partial Response (VGPR) O5 - Partial Response (PR) *A dditional Options Listed Below
8. If Lymphoma, record the disease status pre-transplant: (BLL YMPHO)	O1 - Disease Untreated O2 - Primary Induction Failure - Resistant O3 - Primary Induction Failure - Sensitive O4 - Primary Induction Failure - Sensitivity Unknown O5 - 1st Complete Remission *A dditional Options Listed Below
9. If Other Disease, specify primary diagnosis pre-transplant:(BLOTHPRE)	
10. If Other Disease, record the disease status pre-transplant:(BLOTDXST)	
Indicate the agents used for the patient's conditioning regimen. 11. Cyclophosp hamide:(BLCYCLOS)	☐ 1 - Yes ☐ 2 - No
12. TBI (Total Body Irradiation): (BLTBI)	☐ 1 - Yes ☐ 2 - No
13. Bulsulfan: (BLBULSUL)	☐ 1 - Yes ☐ 2 - No
14. Fludarabine: (BLFLUDAR)	☐ 1 - Yes ☐ 2 - No
15. Melphalan:(BLMELPHA)	☐ 1 - Yes ☐ 2 - No
16. AT G (thymoglobulin): (BLATG)	☐ 1 - Yes ☐ 2 - No
17. Other agent: (BLOTHCON)	1 - Yes 2 - No

O1 - 100 (Normal; No Complaints /Fully Active) O2 - 90 (Normal Activity/Minor Restriction in S trenuous Play) O3 - 80 (Normal Activity with E ffort/Restricted in S trenuous Play) O4 - 70 (Unable to Carry On Normal Activity/Less Time S pent in Pla O5 - 60 (Requires Occasional A ssistance/Minimal Active Play) *A dditional Options Listed Below			
(mm/dd/yyyy)			
(xxx.x) kg OR (BLWTLB) (xxx) lbs			
(mm/dd/yyyy)			
(xxx.xx) cm OR (BLHTIN) (xx.xx) in			
(mm/dd/yyyy)			
☐ 1 - Yes ☐ 2 - No			
(mm/dd/yyyy)			
☐ 1 - Yes ☐ 2 - No			
☐ 1 - Yes ☐ 2 - No			
(mm/dd/yyyy)			

Additional Selection Options for BL6

Patient's primary diagnosis pre-transplant:

- 06 Myelodysplastic (MDS)/ Myelopro life rative (MPS) Disorders
- 07 Multiple Myeloma/ Plasma Cell Disorder (PCD)
- 08 Non-Hodgkin Lymphoma
- 09 Hodgkin Lymphoma
- 10 Solid Tumors
- 11 Severe Aplastic Anemia
- 12 Inherited Abnormalities of Erythrocyte Differentiation or Function
- 13 Disorders of the Immune System
- 14 Inherited Abnormalities of Platelets
- 15 Inherited Disorders of Metabolism
- 16 Histiocytic Disorders
- 17 Autoimmune Disorders
- 99 Other Disease

If Acute Leukemia, record the disease status pre-transplant:

- 6 Third or Subsequent Complete Remission
- 7 Third or Subsequent Relapse
- 8 Previously Untreated

If MDS/MPS, record the disease status pre-transplant:

- 6 Refractory Anemia with Excess Blasts 2 (10-20% blasts)
- 7 Myelodysplastic Syndrome, Unclassified
- 8 MDS Associated with Isolated Del(5q)
- 9 Chronic Myelomonocytic Leukemia

If Multiple Myeloma/PCD, record the disease status pre-transplant:

- 06 Stable Disease (SD)
- 07 Progressive Disease
- 08 Relapse from CR

If Lymphoma, record the disease status pre-transplant:

- 06 2nd Complete Remission
- 07 3rd or Subsequent Complete Remission
- 08 1st Complete Remission Undetermined
- 09 2nd Complete Remission Undetermined
- 10 3rd or Subsequent Complete Remission Undetermined
- 11 1st Relapse Untreated
- 12 1st Relapse Resistant
- 13 1st Relapse Sensitive
- 14 1st Relapse Sensitivity Unknown
- 15 2nd Relapse Untreated
- 16 2nd Relapse Resistant
- 17 2nd Relapse Sensitive
- 18 2nd Relapse Sensitivity Unknown
- 19 3rd or Subsequent Relapse Untreated
- 20 3rd or Subsequent Relapse Resistant 21 - 3rd or Subsequent Relapse - Sensitive
- 22 3rd Relapse or Greater Sensitivity Unknown

What is the patient's Karnofsky score?

- 06 50 (Requires Considerable Assistance/No Active Play)
- 07 40 (Disabled/Able to Initiate Quiet Activities)
- 08 30 (Severely Disabled/Needs Assistance for Quiet Play)
- 09 20 (Very Sick/Limited to Very Passive Activity)
- 10 10 (Moribund; Completely Disabled)

Cancer and Treatment Distress - 0902 (CTX)

Web Version: 1.0; 2.00; 10-16-15

Seg	ment <i>(PF</i>	ROTSEG):
V is it	Number	(VISNO):

a rumber (17010).									
Date of Assessment (CTX DATAS)		(mm/dd.	/уууу)						
Below are thoughts many people have during or after treatment. Some of t	he events below may di	stress o	r worry you,	even if the	y have not happe				
For each statement, please circle how much <u>distress or worry</u> (such as fo	eeling upset, tense, sad	, frustra	ted) it cause	d you in t h	e PAST WEEK.				
WHETHER OR NOT THE EVENT HAS OCCURRED, rate how much DIS	TRESS or WORRY it ca	aused yo	ou in the PA S	ST WEEK:					
None Mild Moderate Severe Not Answ									
Me dical problems.	(CTXMEDPR) 0	□ 1	□ 2	□ 3	□ 88				
2. Not being able to do what I used to do.	(CTXNOTDO) □ 0	□ 1	□ 2	□ 3	□ 88				
3. Long term effects of treatment.	(CTXLNGTM) 🗆 о	□ 1	□ 2	□ 3	□ 88				
Dealing with the medical system.	(CTXMEDSY) □ 0	□ 1	□ 2	□ 3	□ 88				
5. Wondering about the emotional toll on my family or other care givers.	(СТХЕМОТ) 🗆 0	□ 1	□ 2	□ 3	□ 88				
6. Changes in my appearance.	(CTXCHAPP) \square 0	□ 1	□ 2	□ 3	88				
7. Dealing with insurance.	(CTXINSUR) 0	□ 1	□ 2	□ 3	□ 88				
8. Not knowing what the future will bring.	(CTXFUTUR) \square 0	□ 1	□ 2	□ 3	88				
9. Getting information when I need it.	(CTXINFOR) 0	□ 1	□ 2	□ 3	88				
10. Thinking about possible things that could go wrong.	(CTXWRONG) 0	□ 1	□ 2	□ 3	88				
11. Feeling tired or worn out.	(CTXTIRED) 🗆 0	□ 1	□ 2	□ 3	□ 88				
12. The family having to help out more than in the past.	(CTXFAMLY) 0	□ 1	□ 2	□ 3	88				
13. My hair thinning or falling out.	(CTXHAIR) \square 0	□ 1	□ 2	□ 3	88				
14. Wondering how to support myself and the family financially.	(CTXSUPRT) \square 0	□ 1	□ 2	□ 3	□ 88				
15. Losing "myself" in all the changes.	(CTXSELF) \square 0	□ 1	□ 2	□ 3	□ 88				
16. Thinking about the possibility of relapse.	(CTXRELPS) 0	□ 1	□ 2	□ 3	□ 88				
17. Communicating with medical people.	(CTXCMMED) 0	□ 1	□ 2	□ 3	□ 88				
18. Being a burden to other people.	(CTXBRDN) 🗆 0	□ 1	□ 2	□ 3	□ 88				
19. Thoughts about the possibility of dying.	(CTXPSDIE) 0	□ 1	□ 2	□ 3	□ ₈₈				
20. The cost of my treatment.	(CTXTRCST) \square 0	□ 1	□ 2	□ 3	□ 88				
21. Not feeling as masculine or feminine as I used to feel.	(CTXMSFEM) \square 0	□ 1	□ 2	□ 3	□ 88				
22. Not having my usual energy.	(CTXNONRG) 0	□ ₁	□ ₂	□ 3	□ 88				

In the PAST WEEK, how much did your DISTRESS or WORRY INTERFERE with:

	Interfered Not at all	Interfered A Little	Interfered Moderately	Interfered A Lot	Not Answered
23. General activities.	(CTXGNACT) \square 0	□ 1	□ 2	□ 3	□ 88
24. Work.	(CTXWORK) 🗆 0	□ 1	□ 2	□ 3	□ 88
25. Sleep.	(CTXSLEEP) 🗆 0	□ 1	□ 2	□ 3	□ 88

26. Enjoyment of life.	(CTXENJLF) 0	□ 1	□ 2	□ 3	□ 88	
27. Relations with other people.	(CTXRELPP) \square 0	□ 1	□ 2	□ 3	□ 88	
KL Syrjala, copyright 1993, Revise	d 1996, 2000, 2005, Fre	ed Hutchinson Canc	er Research Center, All F	Rights Reserved		
Comments:(CTXCOMM)						

Demographics (DEM)

Web Version: 1.0; 6.02; 12-02-15

1 - Male 2 - Female
(mm/dd/yyyy)
1- Hispanic or Latino 2- NotHispanic or Latino 8- Unknown 9- NotAnswered
White 10 - White (Not O therwise Specified) 11 - European (Not Otherwise Specified) 13 - Mediterranean 14 - White North American *Additional Options Listed Below
White 10 - White (Not 0 therwise Specified) 11 - European (Not 0 therwise Specified) 13 - Mediterranean 14 - White North American *Additional Options Listed Below

Additional Selection Options for DEM

- 15 South or Central American
- 16 Eastern European
- 17 Northern European
- 18 Western European
- 81 White Caribbean
- 82 North Coast of Africa
- 83 Middle Eastern

Black

- 20 Black (Not Otherwise Specified)
- 21 African American 22 African Black (Both Parents Born in Africa)
- 23 Caribbean Black
- 24 South or Central American Black
- 29 Black, Other Specify

Asian

- 30 Asian (Not Otherwise Specified)
- 31 Indian/South Asian
- 32 Filipino (Pilipino)
- 34 Japan ese
- 35 Korean
- 36 Chinese
- 37 Other Southeast Asian
- 38 Vietnamese
- American Indian or Alaska Native
- 50 Native American (Not Otherwise Specified)
- 51 Native Alaskan/Eskimo/Aleut
- 52 American Indian (Not Otherwise Specified)
- 53 North American Indian
- 54 South or Central American Indian
- 55 Caribbean Indian

Native Hawaii an or Other Pacific Islander

- 60 Native Pacific Islander (Not Otherwise Specified)
- 61 Guamanian
- 62 Hawaiian
- 63 Samoan

Other

- 88 Unknown
- 90 Other, Specify
- 99 Not Answered

Death Form (DTH)

Web Version: 1.0; 4.14; 11-05-15

1. Record date of death: (DTHDT)	(mm/dd/yyyy)
2. Was an autopsy performed? (AUTPERF)	☐ 1-Yes ☐ 2-No
	If yes, attach de-identified autopsy report or death summary to the form below.
Enter appropriate cause of death code below. List in order of decreasing	severity.
3. Primary cause of death: (CZDTHPRM)	1.0 - Graft Rejection or Failure
	Infection (Other than Interstitial Pneumonia)
	1.1 - Autologous Recovery
	1.2 - Rejection
	2.1 - Bacterial
	*A dditional Options Listed Below ?
Specify other: (DTHSPEC1)	
4. Secondary cause of death: (SCNDCZ1)	1.0. Confi Dala offen ou Fallema
,	1.0 - Graft Rejection or Failure Infection (Other than Interstitial Pneumonia)
	1.1 - Autologous Recovery
	1.2 - Rejection
	2.1 - Bacterial
	*A dditional Options Listed Below
Specify other: (DTHS PEC2)	
5. Secondary cause of death: (SCNDCZ2)	1.0 - Graft Rejection or Failure
	Infection (Other than Interstital Pneumonia)
	1.1 - Autologous Recovery
	1.2 - Rejection
	2.1 - Bacterial
	*Additional Options Listed Below
Specify other: (DTHS PEC3)	
6. Secondary cause of death: (SCNDCZ3)	1.0 - Graft Rejection or Failure
	Infection (Other than Interstitial Pneumonia)
	1.1 - Autologous Recovery
	1.2 - Rejection 2.1 - Bacterial
	*A dditional Options Listed Below
Specify other: (DTHSPEC4)	
7. Secondary cause of death: (SCNDCZ4)	1.0 - Graft Rejection or Failure
	Infection (Other than Interstitial Pneumonia)
	1.1 - Autologous Recovery
	1.2 - Rejection 2.1 - Bacterial
	*A dditional Options Listed Below
0(bth(DTU0.PF05)	
Specify other: (DTHS PEC5)	
Comments:(DTCMMNTS)	
Comments.(D1 Comment O)	

Additional Selection Options for DTH

Primary cause of death:

- 2.2 Fungal
- 2.3 Viral 2.4 - Protozoal
- 2.5 Other, Specify Below
- 2.9 Organism Not Identified

Interstitial Pneumonia

- 3.1 Viral, CMV
- 3.2 Viral. Other
- 3.3 Pneumocystis
- 3.4 Other, Specify Below
- 3.9 Idiopathic
- 4.0 Adult Respiratory Distress Syndrome
- 5.0 Acute GVHD
- 6.0 Chronic GVHD
- 7.0 Recurrence or Persistence of Leukemia/Malignancy/MDS
- 7.1 Persistent Disease

Organ Failure (Not Due to GVHD or Infection)

- 8.1 Liver
- 8.2 Cardiac (Cardiomyopathy)
- 8.3 Pulmonary
- 8.4 CNS
- 8.5 Renal
- 8.6 Other, Specify Below
- 8.7 Multiple Organ Failure, Specify Below
- 8.8 Secondary Graft Failure
- 9.0 Secondary Malignancy
- 9.1 EBV
- 9.2 Other, Specify Below
- Hemorrhage
- 10.1 Pulmonary
- 10.2 Intracranial
- 10.3 Gastrointestinal
- 10.4 Hemorrhage Not Specified
- 10.5 Other, Specify Below

Vascular

- 11.1 Thromboe mbolic
- 11.2 Disseminated Intravascular Coagulation (DIC)
- 11.3 Gastrointestinal
- 11.4 Thrombotic Thrombocytopenic Purpura
- 11.5 Vascular Not Specified
- 11.9 Other, Specify Below
- 12.0 Accidental Death
- 13.0 Other, Specify Below

Blood and Marrow Transplant Clinical Trials Network		
09	902B (ENR)	Web Version: 1.0; 2.00; 05-09-1
1. Select the type of transplant procedure planned within 6 weeks:(TXTYPESB)	1 - Autologous / Syngeneic 2 - Myeloablative Allogeneic 3 - Reduced Intensity / Non-Myeloablative Allogeneic	
Verify that the patient completed all items on the baseline question naires be for 2. Has the participant completed all baseline question naires? (QUESTESB)	re proceeding with enrollment in Segment B.	
Comments:(COMMESB)		

Follow Up Stat	us Form - 0902 (FU9)
Segment (PROTSEG):	Web Version: 1.0; 3.00; 10-16-19
Visit Number (VISNO):	
1. Date of last contact:(FU9LCTDT)	(mm/dd/yyyy)
Since the date of the last visit indicate if any of the	ne following have occurred:
2. Has the patient died?(FU9DIEED)	1 - Yes 2 - No If Yes, a Death Form must be submitted.
3. Date of patient death:(FU9DTHDT)	(mm/dd/yyyy)
4. Has the patient been hospitalized?(FU9HOSPT)	1 - Yes 2 - No If Yes, a Re-Admission Form must be submitted.
5. Date of hospitalization: (FU9 HO SDT)	(mm/dd/yyyy)
 Has the patient experienced any Unexpected, Grade 3-5 Adverse Events, which are possibly, probably, or definitely associated with participation in the study? (FU9UAE) 	☐ 1 - Yes ☐ 2 - No
 Date of onset of Unexpected, Grade 3-5 Adverse Event, which is possibly, probably or definitely associated with participation in the study: (FU9UAEDT) 	If Yes, an Unexpected, Grade 3-5 Adverse Event Form must be submitted. (mm/dd/yyyy)
8. Has the patient had a Day 30 booster intervention? (FU930BST)	☐ 1 - Yes ☐ 2 - No
9. Type of contact (FU930SP)	1 - Clinical Visit 2 - Telephone Assessment
10. Date of Day 30 booster intervention: (FU930DT)	(mm/dd/yyyy)
11. If No, indicate reason for missed booster intervention:(FU930NO)	
12. Has the patient had a Day 60 booster intervention? (FU960BST)	1 - Yes 2 - No
13. Type of contact (FU960SP)	1 - Clinical Visit 2 - Telephone Assessment
14. Date of Day 60 booster intervention: (FU960DT)	(mm/dd/yyyy)
15. If No, indicate reason for missed booster intervention:(FU960NO)	
16. What was the method of data collection for the patient's Day 30 assessments? (FU930DAT)	1 - Self-administered 2 - Interviewer-administered
17. What was the method of data collection for the patient's Day 60 assessments? (FU960DAT)	1 - Self-administered 2 - Interviewer-administered
18. What was the method of data collection for the patient's Day 100 assessments? (FU9100SP)	1 - Self-administered 2 - Interviewer-administered
19. What was the method of data collection for the patient's Day 180 assessments? (FU9180SP)	1 - Self-administered 2 - Interviewer-administered
20. Has the patient received a second transplant?(FU9TXTWO)	1 - Yes 2 - No
21. Date of second transplant (FU9TXTDT)	(mm/dd/yyyy)
22. Has the patient experienced a relapse?(FU9RELPS)	1 - Yes 2 - No

(mm/dd/yyyy)

23. Date of relapse: (FU9RLPDT)

Comments:(FU9COMM)	

Blood and Marrow Transplant Clinical	
Trials Network	

Intervention Credibility- 0902 (INT)

Web Version: 1.0; 1.02; 10-16-15

		II	iterventic	on Credit	onity- 0902 (INT)	
Segment (PROTSEG):					Web	Version:
Visit Number (VISNO):						
Date of Assessment (INTDT)					(mm/dd/yyyy)	
1. How effective do you think the p	rogram you re	ceived as part	of the study w	ill be in improvi	ing your quality of life during and after your transplant?	
(INTEFFCT) \square 0 \square 1	□ 2	□ 3	□ 4	□ 5	□ 6	
Not at all Effective					Extremely Effective	
2. How skillful and knowledgeable	do you consid	er the person	who explained	the program to	you?	
(INTSKILL) \square 0 \square 1	□ 2	□ 3	□ 4	□ 5	□ 6	
Not at all Skillful					Extremely Skillful	
3. How important do you think it is	that we make	this program a	vailable to oth	er transplant pa	atients?	
(INTIMPT) □ 0 □ 1	□ 2	□ 3	□ 4	□ 5	□ 6	
Not at all Important					Extremely Important	
Comments:(INTCOMM)						

3.00; 10-16-15

-		
Leisure Sc	ore Index- 0902 (LSI)	
	(20.7)	Web Version: 1.0;
Segment (PROTSEG): Visit Number (VISNO):		
Date of Assessment (LSIDT)	(mm/dd/yyyy)	
Please report the frequency, average duration, and exertion level of any	exercise OVER THE PAST WEEK in the spaces be	pelow.
A. STRENUOUS EXERCISE (HEART BEATS RAPIDLY, SWEATING) Examples: running, jogging, vigorous swimming, vigorous long distance bicyc	eling, vigorous aerobic dance classes.	
Did you do any strenuous exercise over THE PAST WEEK?		
(LSISEWK) 1 - No 2 - Yes 88 - Not Answered		
1. What was the frequency of strenuous exercise?(LSISEFRQ)	(xxx) times	
2. What was the average duration of strenuous exercise?(LSISEDUR)	(xxx) minutes	
3. What was the exertion level? (LS/SELVL)	6 no exertion at all 7 extremely light	
	8	
	9 very light 10	
	*Additional Options Listed Below	
B. MODERATE EXERCISE (NOT EXHAUSTING, LIGHT PERSPIRATION) Examples: fast walking, tennis, easy bicycling, easy swimming, popular and f	olk dancing.	
Did you do any moderate exercise over THE PAST WEEK?		
(LSIMEWK) 1 - No 2 - Yes 88 - Not Answered		
4. What was the frequency of moderate exercise? (LSIMEFRQ)	(xxx) times	
5. What was the average duration of moderate exercise? (LSIMEDUR)	(xxx) minutes	
6. What was the exertion level? (LSIMELVL)	6 no exertion at all	
	7 extremely light	
	8 9 very light	
	10	
	*Additional O ptions Listed Below	
C. MILD EXERCISE (MINIMAL EFFORT, NO PERSPIRATION) Examples: easy walking, yoga, bowling, shuffleboard, horseshoes, golf.		
Did you do any mild exercise over THE PAST WEEK?		
(LSIMLWK) 1 - No 2 - Yes 88 - Not Answered		
7. What was the frequency of mild exercise? (LSIMLFRQ)	(xxx) times	
8. What was the average duration of mild exercise? (LSIMLDUR)	(xxx) minutes	
9. What was the exertion level? (LSIMLLVL)	6 no exertion at all	
	7 extremely light	
	8 9 very light	
	10	
	*Additional Options Listed Below	

D. STRENUOUS EXERCISE (HEART BEATS RAPIDLY, SWEATING) Examples: running, jogging, vigorous swimming, vigorous long distance bicyc.	ling, vigorous a erobic dance classes.
Did you do any strenuous exercise over THE PAST MONTH? (LSISEMTH) 1 - No 2 - Yes 88 - Not Answered	
(LSISEMITH) LI-NO LIZ-1es LI 00-INULALISWEIEU	
10. What was the frequency of strenuous exercise?(LSISEMFQ)	(xxx) times
11. What was the average duration of strenuous exercise?(LSISEMDR)	(xxx) minutes
12. What was the exertion level?(LSISEMLV)	6 no exertion at all
	7 extremely light 8
	9 very light
	10 *Additional O ptions Listed Below
E. MODERATE EXERCISE (NOT EXHAUSTING, LIGHT PERSPIRATION) Examples: fast walking, tennis, easy bicycling, easy swimming, popular and for	olk dancing.
Did you do any moderate exercise over THE PAST MONTH?	
(LSIMEMTH) 1 - No 2 - Yes 88 - Not Answered	
13. What was the frequency of moderate exercise?(LSIMEMFQ)	(xxx) times
14. What was the average duration of moderate exercise?(LSIMEMDR) 15. What was the exertion level?(LSIMEMLV)	(xxx) minutes
10. What was no exerteen over 120	6 no exertion at all 7 extremely light
	8
	9 very light 10
	*Additional O ptions Listed Below
F. MILD EXERCISE (MINIMAL EFFORT, NO PERSPIRATION) Examples: easy walking, yoga, bowling, shuffleboard, horseshoes, golf.	
Did you do any mild exercise over THE PAST MONTH?	
(LSIMLMTH) 1 - No 2 - Yes 88 - Not Answered	
16. What was the frequency of mild exercise? (LSIMLMFQ)	(xxx) times
17. What was the average duration of mild exercise? (LSIMLM DR)	(xxx) minutes
18. What was the exertion level? (LSIMLMLV)	6 no exertion at all
	7 extremely light 8
	9 very light
	*Additional O ptions Listed Below
Comments:(LSICOMM)	

Additional Selection Options for LSI

What was the exertion level?

- 12 13 somewhat hard
- 14 15 hard (heavy)

- 16 nard (neavy) 16 17 very hard 18 19 extremely hard 20 maximal exertion

Pittsburgh Sleep Quality Index - 0902 (PSQ)

Web Version: 1.0; 1.01; 10-16-15

Segment (PROTSEG): Visit Number (VISNO):	
Date of Assessment (PSQASTDT)	(mm/dd/yyyy)
The following questions relate to your usual sleep habits during the PAST WEEP nights in the past week. Please answer all questions. 1. During the past week, when have you usually gone to bed at night? USUAL BED TIME(PSQBEDTM)	(ONLY. Your answers should indicate the most accurate reply for the majority of days and AM PM (hh:mm) (PSQBAMPM)
2. During the past week, how long (in minutes) has it usually taken you to fall asleep	
NUMBER OF MINUTES(PS QSLPMN)	
	(xxx) minutes
3. During the past week, when have you usually gotten up in the morning? USUAL GETTING UP TIME (PSQ GUPTM)	AM PM (hh:mm) (PSQGAMPM)
4 During the past week how many hours of estual clean did you get a night? (This	
4. During the past week, how many hours of actual sleep did you get a night? (This HOURS OF SLEEP PER NIGHT (PSQSLPNH)	(xx) Hours (PSQSLPNM) (xx) minutes
For each of the remaining questions, check the hest response. Please answer all	questions
For each of the remaining questions, check the best response. Please answer al 5. During the past week, how often have you had trouble sleeping because you cannot get to sleep within 30 minutes? (PSQSL 30M)	1 - Notat all 2 - A few (1-2) times 3 - Several (3-5) times 4 - Every night or almost every night 9 - Notanswered
6. During the past week, how would you rate your sleep quality overall? (PSQSLOQ)	1 - Very Good 2 - Fairly Good 3 - Fairly Bad 4 - Very Bad 9 - Notanswered
7. During the past week, how often have you taken medicine (prescribed or "over the counter") to help you sleep?(PSQSLAID)	1 - Notatall 2 - A few (1-2) times 3 - Several (3-5) times 4 - Every night or almostevery night 9 - Notanswered
Comments:(PSQCMNTS)	

Intervention Recording Form - 0902 (REC)

Web Version: 1.0; 1.00; 10-16-15

Date Form Entered (DATENTER):

- 1. Name of BMT CTN 0902 interventionist: (RECNAME)
- 2. Date intervention was recorded: (RECINTDT)
- 3. Indicate the patient's intervention arm:(RECARM)
- 4. In dicate the intervention recording number: (RECNUMBR)

Comments:(RECCOMM)

	(mm/dd/yyyy)
1 - Exercise Ir	ntervention
	nagement Intervention
3 - Combinato	on of Exercise and Stress Management Intervention
4 - Standard	of Care Intervention
(xx	x)

SF-36v2 Health Survey- Acute (SFA)

Web Version: 1.0; 1.01; 10-16-15

Segment (PROTSEG): Visit Number (VISNO):

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.

For each of the following questions, please select the choice that best describes your answer.

Date of assessment: (SFADATE) (mm/dd/yyyy) 1. In general, would you say your health is:(SFGENHLT) 1 - Excellent 2 - Very Good 3 - Good 4 - Fair 5 - Poor *Additional Options Listed Below 2. Compared to one week ago, how would you rate your health in general 1 - Much better than one week ago now?(SFCOMPWK) 2 - Somewhat better now than one week ago 3 - About the same as one week ago 4 - Somewhat worse than one week ago 5 - Much worse than one week ago *A dditional Options Listed Below 3. The following questions are about activities you might do during a typical day. Does your health now limit you in these activities? If so, how much? **Activities Amount of Limitation** a. Vigorous activities, such as running, lifting 1 - Yes, limited a lot he avy objects, participating in strenuous sports 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete (SFVIGOR) b. Moderate activities, such as moving a table, 1 - Yes, limited a lot pushing a vacuum cleaner, bowling, or playing golf 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete (SFMODERA) c. Lifting or carrying groceries 1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete (SFGROCRY) d. Climbing several flights of stairs 1 - Yes, limited a lot 2 - Yes, limited a little 3 - No not limited at all 9 - Subject did not complete (SFCLIMBS) e. Climbing one flight of stairs 1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete (SF1CLIMB) f. Bending, kneeling, or stooping 1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, not limited at all

9 - Subject did not complete

(SFBEND)

g. Walking <u>more than a mile</u>	1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete
h. Walking <u>several hundred yards</u>	1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete
i. Walking <u>one hundred yards</u>	1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, not limited at all 9 - Subject did not complete
	(SFWALK1H)
j. Bathing or dressing yourself	1 - Yes, limited a lot 2 - Yes, limited a little 3 - No, notlimited atall 9 - S ubject did not complete

4. During the past week, how much of the time have you had any of the following problems with your work or other regular daily activities as a result of your physical health?

Physical Work Limitations	Amount of Time
a. Cut down on the <u>amount of time</u> you spent on work or other activities	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Listed Below
b. Accomplished less than you would like	1 - All of the time 2 - Most of the time 3 - S ome of the time 4 - A little of the time 5 - None of the time *Additional O ptions Listed Below
c. Were limited in the $\underline{\text{kind}}$ of work or other activities	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Listed Below (SFPHLIMT)
d. Had <u>difficulty</u> performing the work or other activities (for example, it took extra effort)	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Listed Below

5. During the <u>past week</u>, how much of the time have you had any of the following problems with your work or other regular daily activities <u>as a result of any emotional problems</u> (such as feeling depressed or anxious)?

Emotional Work Limitations

Amount of Time

a. Cut down on the $\underline{\text{amount of time}}$ you spent on work or other activities

1 - All of the time 2 - Mostofthe time

3 - Some of the time

4 - A little of the time

5 - None of the time

*Additional Options Listed Below

(SFEPTIME)

b. <u>Accomplished less</u> than you would like	3 - S ome 4 - A little 5 - None	the time of the time al O ptions Listed Below				
c. Did work or other activities less carefully than usual	3 - Some 4 - A little 5 - None	he time of the time of the time of the time of the time al Options Listed Below				
6. During the <u>past week</u> , to what extent has your physic problems interfered with your normal social activities neighbors, or groups?(SFHLTHEX)		1 - Notatall 2 - Slighty 3 - Moderately 4 - Quite a bit 5 - Extremely *A dditional Options Lis	ted Below			
7. How much <u>bodily</u> pain have you had during the <u>past s</u>	week?(SFBODYPN)	1 - None 2 - Very mild 3 - Mild 4 - Moderate 5 - Severe *A dditional Options Lis	ited Below			
8. During the <u>past week</u> , how much did <u>pain</u> interfere wi (including both work outside the home and housewor		1 - Notatall 2 - A little bit 3 - Moderately 4 - Quite a bit 5 - Extremely *A dditional Options Lis	ted Below			
9. These questions are about how you feel and how thin way you have been feeling. How much of the time du		ring the past week. For each	ch question,	please give th	neone answertha	at comes closest to the
a. Did you feel full of life? (SFFLFULL	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Li	sted Below				
b. Have you been very nervous? (SFFLNER)	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options L	isted Below				
c. Have you felt so down in the dumps that nothing could cheeryou up?	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *A dditional Options					
d. Have you felt calm and peaceful? (SFFLCALI)	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options L	is ted Below				

e. Did you have a lot of energy?	(SFFLENRG)	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Li	sted Below
f. Have you felt down hearted and depressed?	(SFFLDEPR)	1 - All of the time 2 - Mostof the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Li	sted Below
g. Did you feel worn out?	(SFFLWORN)	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *A dditional Options L	isted Below
h. Have you been happy?	(SFFLHPPY)	1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *Additional Options Lis	s ted Below
i. Did you feel tired?		1 - All of the time 2 - Most of the time 3 - S ome of the time 4 - A little of the time 5 - None of the time *Additional O ptions Lis	ted Below
10. During the <u>past week</u> , how much of the <u>emotional problems</u> interfered with your relatives, etc.)?(SFHLTHAM)			1 - All of the time 2 - Most of the time 3 - Some of the time 4 - A little of the time 5 - None of the time *A dditional Options Listed Below
11. How TRUE or FALSE is <u>each</u> of the foll a. I seem to get sick a little easier th	•	•	1 - Definitely true 2 - Mostly true 3 - Don't know 4 - Mostly false 5 - Definitely false *A dditional Options Listed Below
b. I am as health y as anybody I kno	w(SFHEALTH)		1 - Definitely true 2 - Mostly true 3 - Don't know 4 - Mostly false 5 - Definitely false *Additional Options Listed Below
c.Texpect my health to get worse(S	SFWORSE)		1 - Definitely true 2 - Mostly true 3 - Don't know 4 - Mostly false 5 - Definitely false *A dditional Options Listed Below

d. My health is excellent (SFEXCLNT)	1 - Definitely true 2 - Mostly true 3 - Don't know 4 - Mostly false 5 - Definitely false *A dditional Options Listed Below
SF-36v2™ Health Survey copyright 1992, 2000 QualityMetric Incorporated and SF-36® is a registered trademark of Medical Outcomes Trust. (SF-36v2 Acute,	
The following questions also ask for your views about your health. For e	ach question, please select the option that best describes your answer. \ensuremath{e}
12. How much <u>nausea</u> have you had during the <u>past week</u> ?(SFNAUSEA)	1 - None 2 - Very mild 3 - Moderate 4 - Severe 5 - Very Severe *A dditional Options Listed Below
During the <u>past week</u> , how much did nausea interfere with your normal work (including both work outside the home and housework)? Select one. (SFNAUSIN)	1 - Notatall 2 - Slighty 3 - Moderately 4 - Quite a bit 5 - Extremely *A dditional Options Listed Below
Comments:(SFACOMM)	

Additional Selection Options for SFA

In general, would you say your health is:

9 - Subject did not complete

Compared to one week ago, how would you rate your health in general now?

9 - Subject did not complete

Physical Time Cut Down

9 - Subject did not complete

During the <u>past week</u>, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?

9 - Subject did not complete

How much bodily pain have you had during the past week?

- 6 Very severe
- 9 Subject did not complete

During the past week, how much did pain interfere with your normal work (including both work outside the home and housework)?

9 - Subject did not complete

I seem to get sick a little easier than other people

9 - Subject did not complete

How much nausea have you had during the past week?

9 - Subject did not complete

Stages of Change Form for Exercise - 0902 (SOC) Web Version: 1.0; 2.00; 10-16-15 Segment (PROTSEG): Visit Number (VISNO): Date of Assessment (SOCDT) (mm/dd/yyyy) Regular exercise is any planned physical activity (e.g., brisk walking, aerobics, jogging, bicycling, swimming, rowing, etc.) performed to increase physical fitness. Such activity should be performed 3-5 times per week for at least 20-30 minutes per session. Question: 1. Do you exercise regularly according to that definition?(SOCEXREG) 1 - Yes, I have been for MORE than 3 months. 2-Yes, I have been for LESS than 3 months. 3 - No, but I intend to in the next 30 days. 4 - No, but I intend to in the next 3 months. 5 - No, and I do NOT intend to in the next 3 months. *Additional Options Listed Below Comments:(SOCCOMM)

Additional Selection Options for SOC

Do you exercise regularly according to that definition? 88 - Not Answered

Stress Reduction Checklist - 0902 (SRC)

Web Version: 1.0; 2.00; 10-16-15

Segment (PROTSEG): Visit Number (VISNO):	
Date of Assessment (SRCDT)	(mm/dd/yyyy)
In the PAST WEEK, have you done any of the following to relieve stress? 1. Practiced deep breathing:(SRCDPBRT) IF YES, how often?(SRCDPBRY) 2. Listened to relaxation audio tapes:(SRCRLXAT) IF YES, how often?(SRCRLXY) 3. Practiced relaxation on your own:(SRCRLXOW) IF YES, how often?(SRCRLXOY) 4. Watched videos/DVDs about managing stress:(SRCVDDVD) IF YES, how often?(SRCVDVDY) 5. Told yourself things to help you cope:(SRCCOPE) IF YES, how often?(SRCCOPEY)	1 - No
Comments:(SRCCOMM)	

Blood and Marrow Transplant Clinical	
Trials Network	

Web Version: 1.0; 15.00; 11-05-15

Trans		
Segment (PROTSEG): Visit Number (VISNO):		Web Version:
1. Record date of initiation of conditioning regimen:(CONDNGDT) 2. Record date of hematopoietic stem cell infusion:(TXDTTXP) 3. Record the patient's pre-transplant CMV antibody (lgG) status:(CMVSTAT) 4. IUBMID for this patient (if available):(T_IUBMID)	(mm/dd/yyyy) (mm/dd/yyyy) 1 - Positive	
Comments:(COMMTXP1)		